← Back to Search

Virus Therapy

RPTR-168 for Melanoma

Phase 1
Waitlist Available
Research Sponsored by Repertoire Immune Medicines
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through approximately 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug, RPTR-168, to see if it is safe for patients with certain types of cancer that haven't responded to other treatments. The drug is given through an IV to see if it can help fight the cancer cells.

Eligible Conditions
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through approximately 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Frequency of dose interruptions
Number of subjects with dose limiting toxicities (DLT)
Secondary study objectives
Area under the serum concentration-time curve
Best overall response
Immunogenicity of RPTR-168 as monotherapy
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RPTR-168Experimental Treatment1 Intervention
Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors and melanoma.

Find a Location

Who is running the clinical trial?

Repertoire Immune MedicinesLead Sponsor
2 Previous Clinical Trials
45 Total Patients Enrolled
1 Trials studying Melanoma
22 Patients Enrolled for Melanoma
Daniel Vlock, MDStudy DirectorRepertoire Immune Medicines
4 Previous Clinical Trials
70 Total Patients Enrolled
David Spriggs, MDStudy DirectorRepertoire Immune Medicines
2 Previous Clinical Trials
45 Total Patients Enrolled
1 Trials studying Melanoma
22 Patients Enrolled for Melanoma
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top